Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7677787980818283848586...123124»
  • ||||||||||  Clinical, Clinical guideline, Review, Journal:  Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. (Pubmed Central) -  Aug 25, 2021   
    Therapies for HCC with robust clinical evidence include transarterial chemoembolization (TACE) and first to second line systemic treatment options (sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab). Immunotherapy with nivolumab and pembrolizumab has failed to show statistical benefit but the novel combination of atezolizumab plus bevacizumab has recently shown survival benefit over sorafenib in frontline.
  • ||||||||||  Journal:  Current treatment options for hepatocellular carcinoma. (Pubmed Central) -  Aug 25, 2021   
    Additional studies are currently underway using other tyrosin kinase inhibitors - regorafenib, lenvatinib and cabozantinib - in combination with nivolumab, ipilimumab and pembrolizumab. This development of treatment at all stages evoked with renewed urgency the need to find a suitable way to search for the early stages of HCC and to create a more effective system for selecting patients for the most appropriate treatment.
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Enrollment open, Trial completion date, Trial primary completion date:  A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Aug 25, 2021   
    P1b,  N=70, Recruiting, 
    This development of treatment at all stages evoked with renewed urgency the need to find a suitable way to search for the early stages of HCC and to create a more effective system for selecting patients for the most appropriate treatment. Active, not recruiting --> Recruiting | Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Feb 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, Checkpoint inhibition:  Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan. (Pubmed Central) -  Aug 21, 2021   
    Furthermore, a significantly longer survival with atezolizumab, which is an immune checkpoint inhibitor, plus bevacizumab was observed compared with sorafenib for unresectable HCC patients. Herein, we review the current status of hepatic resection and liver transplantation for HCC in Japan and discuss the role of hepatic resection in the era of molecular-targeted agents and immune checkpoint inhibitors, as well as the need for a definition of borderline resectable-HCC.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Severe ulcerative skin lesions due to lenvatinib. (Pubmed Central) -  Aug 20, 2021   
    Herein, we review the current status of hepatic resection and liver transplantation for HCC in Japan and discuss the role of hepatic resection in the era of molecular-targeted agents and immune checkpoint inhibitors, as well as the need for a definition of borderline resectable-HCC. No abstract available
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Tumor mutational burden, Metastases:  Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov) -  Aug 20, 2021   
    P2,  N=40, Recruiting, 
    Good Child-Pugh scores and tumor factors may be associated with a better response rate and OS. Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=72, Enrolling by invitation, 
    Trial completion date: Jan 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025 Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Aug 2021
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer. (Pubmed Central) -  Aug 17, 2021   
    Therefore, particularly during the first months of treatment, or at any time of huge reduction of body weight, monitoring of γGT and US is crucial for prompt diagnosis and treatment. Conservative medical treatment and LEN dosage titration, together with dietary and rehabilitative supports, can limit or avoid the need for drug withdrawal and cholecystectomy.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. (Pubmed Central) -  Aug 15, 2021   
    Many studies have indicated that the 67 dysregulated lncRNAs show oncogenic or anti-oncogenic effects in HCC by regulation on epigenetic, transcriptional and post-transcriptional levels and they play pivotal roles in the initiation of HCC in diverse biological processes like proliferation, metastasis, drug resistance, radio-resistance, energy metabolism, autophagy and so on. Besides, many of these lncRNAs are associated with clinicopathological features and clinical prognosis in HCC, which may provide a potential future application in the diagnosis and therapy of HCC.